Fraction of IL-10+ and IL-17+ CD8 T cells is increased in MS patients in remission and during a relapse, but is not influenced by immune modulators

J Neuroimmunol. 2013 May 15;258(1-2):77-84. doi: 10.1016/j.jneuroim.2013.02.014. Epub 2013 Mar 19.

Abstract

In the present study, circulating proportions of CD8(+) T (Tc) cell subsets, including IL-17 (Tc17) and IL-10 (Tc10) producing cells, were assessed in relapsing-remitting MS (RRMS) patients and a possible effect of beta interferon (IFN-β), glatiramer acetate (GA), and vitamin D (VitD) on these cell subsets was investigated. We show that both Tc17 and Tc10 cell fractions are elevated in the circulation of RRMS patients in remission compared to healthy subjects and that these Tc subsets remain unaffected by current immune modulating regimens.

MeSH terms

  • Adult
  • CD8-Positive T-Lymphocytes / immunology*
  • Female
  • Flow Cytometry
  • Glatiramer Acetate
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Interferon-beta / therapeutic use
  • Interleukin-10 / immunology
  • Interleukin-17 / immunology
  • Male
  • Middle Aged
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy
  • Multiple Sclerosis, Relapsing-Remitting / immunology*
  • Peptides / therapeutic use
  • Radioimmunoassay
  • Recurrence
  • Remission Induction
  • T-Lymphocyte Subsets / immunology*
  • Vitamin D / blood

Substances

  • Immunosuppressive Agents
  • Interleukin-17
  • Peptides
  • Interleukin-10
  • Vitamin D
  • Glatiramer Acetate
  • Interferon-beta